Taysha Gene Therapies (TSHA) Competitors $2.41 +0.47 (+24.23%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$2.44 +0.02 (+1.04%) As of 05/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSHA vs. AMPH, ARDX, DYN, AUPH, SNDX, BGM, ADPT, IOVA, WVE, and ETNBShould you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Dyne Therapeutics (DYN), Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Qilian International Holding Group (BGM), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Wave Life Sciences (WVE), and 89bio (ETNB). These companies are all part of the "pharmaceutical products" industry. Taysha Gene Therapies vs. Amphastar Pharmaceuticals Ardelyx Dyne Therapeutics Aurinia Pharmaceuticals Syndax Pharmaceuticals Qilian International Holding Group Adaptive Biotechnologies Iovance Biotherapeutics Wave Life Sciences 89bio Amphastar Pharmaceuticals (NASDAQ:AMPH) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk. Does the MarketBeat Community prefer AMPH or TSHA? Amphastar Pharmaceuticals received 282 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 78.01% of users gave Taysha Gene Therapies an outperform vote while only 65.88% of users gave Amphastar Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39265.88% Underperform Votes20334.12% Taysha Gene TherapiesOutperform Votes11078.01% Underperform Votes3121.99% Which has more risk & volatility, AMPH or TSHA? Amphastar Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Is AMPH or TSHA more profitable? Amphastar Pharmaceuticals has a net margin of 21.80% compared to Taysha Gene Therapies' net margin of -229.67%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals21.80% 26.44% 11.89% Taysha Gene Therapies -229.67%-106.36%-49.16% Do analysts rate AMPH or TSHA? Amphastar Pharmaceuticals currently has a consensus target price of $43.50, indicating a potential upside of 82.16%. Taysha Gene Therapies has a consensus target price of $6.63, indicating a potential upside of 174.90%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, AMPH or TSHA? Amphastar Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$731.97M1.55$137.54M$3.067.80Taysha Gene Therapies$8.33M59.30-$111.57M-$0.36-6.69 Do institutionals & insiders believe in AMPH or TSHA? 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor AMPH or TSHA? In the previous week, Taysha Gene Therapies had 5 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 9 mentions for Taysha Gene Therapies and 4 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.31 beat Taysha Gene Therapies' score of 0.81 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAmphastar Pharmaceuticals beats Taysha Gene Therapies on 10 of the 18 factors compared between the two stocks. Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSHA vs. The Competition Export to ExcelMetricTaysha Gene TherapiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$494.18M$2.95B$5.53B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio3.8330.0722.5118.54Price / Sales59.30494.82397.62103.30Price / CashN/A168.6838.1834.62Price / Book6.033.176.734.25Net Income-$111.57M-$72.35M$3.22B$248.18M7 Day Performance36.93%2.14%1.38%1.03%1 Month Performance82.58%5.67%2.79%2.70%1 Year Performance-6.59%-23.57%15.41%4.05% Taysha Gene Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSHATaysha Gene Therapies1.9624 of 5 stars$2.41+24.2%$6.63+174.9%-0.4%$494.18M$8.33M3.83180Analyst ForecastNews CoverageHigh Trading VolumeAMPHAmphastar Pharmaceuticals4.4239 of 5 stars$23.50+0.6%$43.50+85.1%-43.3%$1.12B$731.97M7.831,620Upcoming EarningsPositive NewsARDXArdelyx4.5656 of 5 stars$4.56-5.4%$10.61+132.7%-17.2%$1.09B$333.62M-28.5090Earnings ReportNews CoveragePositive NewsDYNDyne Therapeutics3.3267 of 5 stars$9.33+14.2%$47.46+408.7%-53.6%$1.06BN/A-2.62100Short Interest ↑High Trading VolumeAUPHAurinia Pharmaceuticals2.6535 of 5 stars$7.66-1.2%$11.50+50.1%+57.7%$1.05B$235.13M-51.06300Positive NewsSNDXSyndax Pharmaceuticals3.6454 of 5 stars$11.93+3.4%$36.20+203.4%-37.1%$1.03B$23.68M-3.29110Upcoming EarningsPositive NewsGap UpBGMQilian International Holding GroupN/A$10.52-4.4%N/AN/A$1.02B$25.10M0.00298Gap DownADPTAdaptive Biotechnologies4.1367 of 5 stars$6.83-6.8%$9.40+37.6%+163.8%$1.01B$178.96M-6.27790Earnings ReportNews CoveragePositive NewsIOVAIovance Biotherapeutics4.5669 of 5 stars$3.08+0.7%$18.22+491.6%-73.4%$1.01B$164.07M-2.07500Upcoming EarningsPositive NewsWVEWave Life Sciences4.3124 of 5 stars$6.12+3.4%$22.18+262.4%+40.0%$939.33M$108.30M-5.51240Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageETNB89bio2.9772 of 5 stars$6.27+3.5%$27.56+339.5%-7.1%$915.32MN/A-2.1540Earnings ReportUpcoming EarningsAnalyst UpgradeNews CoveragePositive News Related Companies and Tools Related Companies AMPH Alternatives ARDX Alternatives DYN Alternatives AUPH Alternatives SNDX Alternatives BGM Alternatives ADPT Alternatives IOVA Alternatives WVE Alternatives ETNB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSHA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TSHA Stock Free TSHA Stock Alerts